There is a number radiopharma loves almost as much as a clinical response rate: isotope production capacity. A new actinium-225 project is announced and we hear how many millicuries or curies it could eventually produce; a new accelerator comes online and we hear about nameplate capacity; a new production route is demonstrated and calculations begin about how much material it might contribute to future global supply.
Those numbers matter because the enormous investment being made in isotope production is one of the reasons radiopharma can contemplate a future with many more targeted alpha therapies than it has today. But if I am developing an actinium-225 radiopharmaceutical, there is another number I care about much more: how much can I actually buy?
Those two concepts are routinely treated as though they are interchangeable, but they aren't. A facility may have the physical capability to produce a certain quantity of an isotope without producing all of that material today, and material that is being produced may not all meet the specifications required by a particular pharmaceutical developer.
Qualified material may also already be committed under long-term agreements to other customers or internally allocated to the producer's own pipeline. Even commercially available material still has to arrive when a customer needs it, meaning several very different numbers can hide behind the word “capacity”: theoretical capacity, installed capacity, demonstrated production, qualified production, committed supply and uncommitted supply actually available for purchase.
For a drug developer trying to schedule manufacturing, those distinctions aren't semantics. They are the difference between an impressive presentation slide and a reliable supply chain.
Nowhere is this more apparent than with actinium-225. The isotope has attracted enormous attention because of the potential of targeted alpha therapy, and companies around the world are developing new production methods and expanding capacity through accelerator-based production, generator-based approaches and other technologies that could create an Ac-225 market considerably larger than the one radiopharma has historically relied upon.
That is unquestionably progress, but a developer doesn't manufacture a radiopharmaceutical with “global Ac-225 capacity.” It manufactures with actual Ac-225 delivered to an actual facility under defined specifications and quality requirements on a particular production schedule.
The source, purity, impurity profile, documentation and regulatory qualification all matter, as do reliability, geography, price and timing. A production facility capable of generating significant quantities of Ac-225 is valuable to the industry, but if most of its output is committed, undergoing qualification, reserved for internal programs or not yet available at commercial scale, that capacity tells a prospective customer relatively little about how much isotope it can actually secure.
Radiopharma also needs to be careful about treating isotope production as a commodity market where one unit of material is automatically interchangeable with another. Different production methods can result in different impurity profiles and downstream processing requirements, while pharmaceutical developers have specifications tied to their manufacturing processes, regulatory filings and product-quality requirements.
Changing an isotope source is therefore not necessarily as simple as calling a different supplier when the original producer cannot deliver. That becomes even more important as programs advance from research into clinical development and eventually commercial production, when a developer needs confidence not merely that isotope exists somewhere in the world, but that its supply chain can repeatedly deliver material suitable for its specific product.
Redundancy matters as well. Having two qualified suppliers capable of reliably supporting a program can be far more valuable than having access to a much larger theoretical pool of production that has never been incorporated into the drug's manufacturing and regulatory strategy.
There is another reason headline production numbers can be misleading: isotopes have to travel through an entire chain before they become medicine. Production is followed by processing, purification, transportation, radiolabeling, quality control, finished-dose manufacturing, distribution and ultimately administration to a patient, with radioactive decay occurring throughout that process.
Inefficiencies or scheduling problems at any point can reduce the amount of initial isotope production that becomes usable clinical product. The number that ultimately matters, then, is not simply how much isotope leaves a production facility, but how many reliable patient doses the entire supply chain can support.
That is a much harder number to calculate, but it is also much closer to the economic reality of radiopharma. If the industry wants to understand whether enough Ac-225 will exist to support dozens of clinical programs and potentially multiple commercial therapies, counting announced production capacity is only the beginning; we also need to understand how efficiently that capacity translates into qualified, deliverable and ultimately administered material.
Isotope producers have good reasons to announce capacity. Developers, investors and potential partners need to understand the scale of the infrastructure being built, and large production capabilities can demonstrate that a company is preparing for future commercial demand.
But as the market matures, customers are going to need greater visibility into a different set of metrics: how much production has actually been demonstrated, how much is currently qualified for pharmaceutical use, how much is contracted, how much remains available to new customers, what delivery schedules can be guaranteed and what redundancy exists if a facility goes offline.
They will also need to know how quickly production can scale when a customer's clinical program advances. Those questions become increasingly important as radiopharma moves from a market characterized by relatively small clinical requirements toward one potentially supporting multiple large commercial products.
The conversation therefore needs to evolve from capacity to availability.
None of this diminishes the extraordinary progress being made in isotope production. The industry needed more Ac-225 sources and companies are building them; it needed new production technologies and those technologies are advancing; it needed substantial capital investment in isotope infrastructure and that investment is happening.
The next stage is turning all of that capacity into a dependable commercial market. Drug developers need qualified suppliers, manufacturers need predictable delivery schedules, hospitals ultimately need finished products, and patients need doses to arrive when their treatments are scheduled.
That chain is what supply actually means. Production capacity remains an important measure of where this industry is heading, but increasingly radiopharma needs an answer to a much more practical question: How much can I buy?
